The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk or favorable intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.
It examines interactions among genes in the tumor to better understand the unique biology of the cancer—a science known as genomics—for prostate cancer patients. Essentially, the Oncotype DX GPS assay provides more specific and individualized information about prostate cancer aggressiveness based on the biology of the tumor. The assay:
Adverse pathology is the presence of high-grade (Gleason Score >4 + 3) and/or non-organ-confined disease (pT3+). It provides an immediate snapshot of the risk of aggressive disease at the time of biopsy.
Biopsy alone often misses patients with high risk of adverse pathology.
These patients have lower risk of disease progression and should consideractive surveillance
These patients have higher risk of disease progression and should consider immediate treatment
The Oncotype DX Genomic Prostate Score test provides a comprehensive risk profile for personalized information to guide treatment decisions.
Oncotype DX GPS assay is proven to be an independent predictor of:
NCCN Guidelines include the GPS assay as a Category 2A molecular testing option for consideration in prostate cancer patients with clinically low-risk and favorable intermediate-risk disease (life expectancy >10 years).
The Oncotype DX GPS assay has been developed and studied in over 4,500 patients.3 The results from the assay refine risk assessment, help guide treatment decisions, and potentially impact patient quality of life.
For more information about the test contact us.
* Kaiser Permanente Northern California (KPNC) retrospective cohort study N=279 clinically low-, intermediate-, and high-risk patients; biopsy. This study estimated 10-year mortality and metastasis risk based on patients after radical prostatectomy. †University of California, San Francisco (UCSF) prospective validation study: N=395 clinically low-risk patients; needle biopsy.